Kenneth Andrews, MD
Otolaryngology · New Britain, CTNPI 1114247798
Payments from drug & device makers
Across 28 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$180
- Intersect ENT, Inc.$168
- Optinose US, Inc.$156
- GSK$51
- Sanofi$43
- Integra Lifesciences Corporation$19
- plus $48 from 3 others
What the payments were for
- Food & beverage$60391%
- Education$629%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 6 | $180 |
| Intersect ENT, Inc. | 6 | $168 |
| Optinose US, Inc. | 8 | $156 |
| GSK | 2 | $51 |
| Sanofi | 2 | $43 |
| Integra Lifesciences Corporation | 1 | $19 |
| Acclarent, Inc | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Phadia US Inc. | 1 | $13 |
How this compares
$665 in reported general payments places this provider in the 30th percentile of 119 otolaryngology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $77,109 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 126 | $11,772 |
| Ipratropium Bromide | 257 | $5,055 |
| Omeprazole | 330 | $3,632 |
| Mometasone Furoate | 71 | $3,098 |
| DymistaAzelastine/Fluticasone | 12 | $2,658 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 25 | $2,268 |
| Azelastine Hcl | 118 | $2,199 |
| Fluticasone Propionate | 178 | $2,195 |
| Fluocinolone Acetonide Oil | 57 | $1,898 |
| Famotidine | 114 | $1,445 |
| Levocetirizine Dihydrochloride | 64 | $1,110 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 19 | $924 |
| Doxycycline Monohydrate | 22 | $556 |
| Gabapentin | 77 | $511 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New Britain
- Sara PaiNew Haven$3.5M
- Richard ManesNew Haven$246K
- Todd FalconeFarmington$171K
- Denis LafreniereFarmington$63K
- Seth BrownFarmington$58K
- Howard StupakWestport$48K
- Belachew TessemaFarmington$45K
- Howard BoeyNew Haven$19K
- Erik WaldmanNew Haven$13K
- Mahesh BhayaWaterbury$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.